Summary: No natural supplement has been shown to replicate the clinical benefits of prescribed GLP-1 or GIP receptor agonists for diabetes management or weight loss
GLP-1 and GIP-based therapies may be appropriate for individuals with Type 2 diabetes, insulin resistance, or those who are overweight (BMI 2730+) with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
If you have questions, please contact your Fisher Phillips attorney, the authors of this Insight, any attorney in our Employee Benefits and Tax Practice Group
A medical consultation is important before starting treatment, especially for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, certain endocrine cancers, pregnancy, breastfeeding, complex diabetes medication use, or a personal or family history of medullary thyroid carcinoma or MEN2